Johnson & Johnson $JNJ Shares Sold by Prosperity Financial Group Inc.

Prosperity Financial Group Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,223 shares of the company’s stock after selling 296 shares during the quarter. Prosperity Financial Group Inc.’s holdings in Johnson & Johnson were worth $798,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after acquiring an additional 1,170,120 shares during the period. Northern Trust Corp grew its stake in Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after acquiring an additional 130,645 shares during the period. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after acquiring an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after acquiring an additional 448,666 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on JNJ shares. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday. Finally, HSBC raised their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Down 0.3%

NYSE JNJ opened at $192.31 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business’s fifty day simple moving average is $181.99 and its 200-day simple moving average is $165.84. The firm has a market cap of $463.15 billion, a PE ratio of 18.56, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.